secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2022-01-05T23:59:59+00:00
Accession:  0001564590-22-000432
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences appoints Javier Szwarcberg as CEO, promotes Samir Gharib to President
--------------------------------------------------------------------------------

- Javier Szwarcberg, M.D., MPH, appointed CEO and director effective Jan 3, 2022; succeeds interim CEO Michael Grey, who remains Executive Chairman.
- Samir Gharib, MBA, promoted to President while continuing as CFO; salary increased to $430,000 with target bonus of 45%.
- Szwarcberg receives options to purchase 1,000,000 shares at $4.59; 750k time-vested over 4 yrs, 250k performance-vested on CAHmelia-204 trial milestones.
- Preliminary cash, cash equivalents and investments estimated at $121.4M as of Dec 31, 2021 (unaudited).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000156459022000432/0001564590-22-000432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000156459022000432/sprb-8k_20211229.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-000432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer